Replies to post #31663 on Anavex Life Sciences Corp (AVXL)

[imho]

The market is looking for results on Saturday that, if repeated in a broader phase 3, would prospectively be adequate for FDA approval. My opinion is that is a relatively low bar given that 2-73 is so well tolerated and that any proven marginal cognitive improvement in AD indications over current standard of care is rare. A low bar that hopefully we will pass.

I hope to see the final Part A results are consistent with the July interim results. That would be "great." And sustained benefit in the interim Part B would be "excellent." I'll voice my grade here tomorrow in case anyone is interested and would love to hear others opinions likewise.

I agree with your assessment and look forward to your "grade" and from the others on this board.

IMHO